Jacobs Levy Equity Management, Inc Aeglea Bio Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $218,091 - $1.16 Million	-436,183 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $546,208 - $1.39 Million	292,090 Added 202.71%	436,183 $1 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $504,325 - $1.21 Million	144,093 New	144,093 $684,000
Q3 2021 Nov 15, 2021	SELL	$6.03 - $7.95 $357,542 - $471,387	-59,294 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.32 - $8.38 $822,478 - $1.09 Million	-130,139 Reduced 68.7%	59,294 $413,000
Q1 2021 May 17, 2021	BUY	$6.76 - $8.57 $494,602 - $627,032	73,166 Added 62.93%	189,433 $1.5 Million
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $878,967 - $1.23 Million	-125,209 Reduced 51.85%	116,267 $915,000
Q3 2020 Nov 16, 2020	BUY	$6.51 - $9.33 $1.57 Million - $2.25 Million	241,476 New	241,476 $1.71 Million
Q2 2020 Aug 17, 2020	SELL	$4.01 - $11.04 $160,011 - $440,529	-39,903 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.51 - $8.48 $140,059 - $338,377	39,903 New	39,903 $186,000
Q3 2019 Nov 14, 2019	SELL	$6.42 - $9.0 $307,216 - $430,677	-47,853 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$6.1 - $8.78 $291,903 - $420,149	47,853 New	47,853 $328,000
Q3 2018 Nov 14, 2018	SELL	$8.24 - $11.0 $110,242 - $147,169	-13,379 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $105,292 - $145,697	13,379 New	13,379 $142,000
Q1 2018 May 15, 2018	SELL	$5.07 - $10.9 $79,538 - $170,999	-15,688 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$4.0 - $5.98 $62,752 - $93,814	15,688	15,688 $85,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.